DePuy prices flotation in the middle of estimated range
This article was originally published in Clinica
Executive Summary
Orthopaedics company DePuy has priced its initial public offering on the New York Stock Exchange at $17.50 a share, in the middle of the price range assumed in the prospectus. Of the 14.8 million shares offered, representing 15% of DePuy, 7.8 million were issued by the company and 7.0 million by its parent Corange, which also owns German diagnostics company Boehringer Mannheim.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.